Recent research has shown that IL-4 and IL-13 promote the function of M-MDSCs and inhibit anti-tumor immunity in intestinal tumors, suggesting IL-4 and IL-13 could be potential targets for improving CRC immunotherapy [79]. The gene discussed is IL4; the disease is neoplasm.